Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells

Cancer Biology and Therapy

Volumn 5, Issue 2, 2006, Pages 189-197

  Chakrabarty, Shilla ^a   Kondratick, Laura ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Obstetrics and Gynecology ^*

Author keywords

Anti IGFBP 2; Cell proliferation; Cytokines; Human epithelial ovarian cancer cells; IGFBP 2; MAP kinase cascades

Indexed keywords

CYTOKINE; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN ANTIBODY; SOMATOMEDIN BINDING PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; OVARY CANCER; PROTEIN EXPRESSION; STRESS;

EID: 33644689975     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.2.2333     Document Type: Article

References (49)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-13.
2. Langdon SP, Smyth JF. Growth factors and ovarian cancer. Endocr Relat Cancer 1998; 5:283-91.
3. Adashi EY, Resnick CE, D'Ercole AJ, Svoboda ME, van Wyk J. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev 1985; 6:400-20.
4. Giordano G, Barreca A, Minuto F. Growth factors in the ovary. J Endocrinol Invest 1992; 15:689-707.
5. Beck EP, Russo P, Gliozza B, Jaeger W, Papa V, Wildt L, Pezzino V, Lang N. Identification of insulin and insulin-like growth factor-I (IGF-I) receptors in ovarian cancer tissue. Gynecol Oncol 1994; 54:196-201.
6. Foekens JA, van Putten WLJ, Portengen H, Rodenburg CJ, Reubi JC, Berns PMJJ, Henzen-Logmans SC, van der Burg MEL, Alexieva-Figusch J, Klijn JGM. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-I (IGF-IR) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 1990; 37:815-21.
7. Foekens JA, van Putten WLJ, Portengen H, Rodenburg CJ, Reubi JC, Henzen-Logmans SC, Alexieva-Figusch J, Klijn JGM. Prognostic value of receptors for epidermal growth factor (EGF-r), insulin-like growth factor-I (IGF-I-r) and somatostatin (SS-r) and of pS2 protein, in patients with breast and ovarian cancer. Eur J Cancer 1990; 154-8.
8. van Dam PA, Vergote IB, Lowe DG, Watson JV, van Damme P, van der Auwera JC, Shepherd JH. Expression of c-erbB-2, c-myc and c-ras oncoproteins, insulin-like growth factor receptor I and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 1994; 47:914-9.
9. Weigang B, Nap M, Bittl A, Jaeger W. Immunohistochemical localization of insulin-like growth factor I receptors in benign and malignant tissues of the female genital tract. Tumor Biology 1994; 15:236-46.
10. Bartlett JMS, Rabiasz GJ, Scott WNLSPHGLLA, Smyth JF, Miller WR. Growth control of human ovarian carcinoma cells by insulin-like growth factors. Oncol Rep 1995; 2:857-62.
11. Hofmann J, Wegmann B, Hackenberg R, Kunzmann R, Schultz K, Havemann K. Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells. J Cancer Res Clin Oncolo 1994; 120:137-42.
12. Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TWSSvHDD, Yee D. Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 1993; 29A:2015-9.
13. Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-I and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 1993; 69:756-60.
14. Yee D, Morales FR, Hamilton TC, von Hoff ED. Expression of insulin-like growth factor I, its binding proteins and its receptor in ovarian cancer. Cancer Res 1991; 51:5107-5112.
15. Flyvberg A, Mogenson O, Mogenson B, Nielsen OS. Elevated serum insulin-like growth factor binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997; 82:2308-13.
16. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996; 73:1069-1073.
17. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994; 78:271-6.
18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995; 16:3-34.
19. Oh Y, Yamanka Y, Wilson E, Kim HS, Vorwerck P, Hwa V. IGF-independent actions of IGFBPs. In: Takano K, Hizuka N, Takahashi SI, eds. Molecular Mechanisms to Regulate the Activities of Insulin-Like Growth Factors. Amsterdam: Elsevier, 1998:123-33.
20. Perks CM, Bowen S, Gill SP, Newcomb PV, Holly JM. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apopotosis of breast epithelial cells. J Cell Biochem 1999; 75:652-64.
21. Chatterjee S, Park ES, Soloff MS. Proliferation of DU145 prostate cancer cells is inhibited by suppressing IGFBP-2. Int J Urol 2004; 11.
22. Wang X, Martindale JL, Liu Y, Holbrook NJ. The cellular response to oxidative stress: Influences of mitogen-activated protein kinase signaling pathways on cell survival. Biochem J 1998; 333:291-300.
23. Xia Z, Dickens M, Raingeaud J, Davies RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-31.
24. Choi KC, Auersperg N, Leung PCK. Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reprod Biol Endocrinol 2003; 1:71.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
26. Charest DL, Mordret G, Harder KW, Jirk F, Pelech SL. Molecular cloning, expression and characterization of the human mitogen-activated protein kinase p44erk1. Mol Cell Biol 1993; 13:4679-90.
27. Sugiura N, Suga T, Ozeki Y, Maniya G, Takishima K. The mouse extracellular signal-regulated kinase 2 gene. Gene structure and characterization of the promoter. J Biol Chem 1997; 272:21575-81.
28. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995; 270:7420-6, (Abstract).
29. Gonzalez FA, Seth A, Raden DL, Bowman DS, Fay FS, Davis RJ. Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus. J Cell Biol 1993; 122:1089-101.
30. Lenormand P, Sardet C, Pages G, L'Allemain G, Burnet A, Pouyssegur J. Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J Cell Biol 1993; 122:1079-88.
31. Menouy M, Binoux M, Babajko S. Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: Modulation by transforming growth factor-bera and retinoic acid. Endocrinology 1997; 138:683-90.
32. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76:1031-5.
33. Figueroa JA, Deraad S, Tadlock L, Speights VO, Rinchart JJ. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998; 159:1379-83.
34. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Parieme C, Goldwasser B, Karasik A. Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993; 77:229-33.
35. De Meyts P, Wallach B, Christoffersen CT, Urso B, Gronskov K, Latus LJ, Yakushiji F, Ilondo MM, Shymko RM. The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 1994; 42:152-69.
36. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15:2760-70.
37. McCormick SD. Effects of growth hormone and insulin-like growth factor I on salinity tolerance and gill Na+, K+ - ATPase in Atlantic salmon (Salmo salar): Interaction with cortisol. Gen Comp Endocrinol 1996; 101:3-11.
38. Whitmarsh AJ, Yang SH, Su MS, Sharrocks AD, Davis RJ. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol 1997; 17:2360-71.
39. Woodgett JRAJ, Kyriakis JM. Regulation of nuclear transcription factors by stress signals. Clin Exp Pharmacol Physiol 1995; 22:281-3.
40. Angel P, Karin M. The role of Jun, Fos and the Ap-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1991; 1072:129-57.
41. Artega CL, Holt JT. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer zenografts in nude mice. Cancer Res 1996; 56:1098-103.
42. Zoumpoulis V, Papassava P, Linardopoulos S, Gillespie D, Balmain A, Pintzas A. High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 2000; 19:4011-21.
43. van Dam H, Wilhelm D, Herr I, Streffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995; 14:1798-811.
44. Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, Miller WR. Experssion of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1995; 1:1603-9.
45. Pizette S, Batoz M, Prats H, Birnbaum D, Coulier F. Production and functional characterization of human recombinant FGF-6 protein. Cell Growth Differ 1991; 2:561-6.
46. Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, LeBourhis X, Boilly B, Peyrat JP, Hondermarck H. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 2001; 276:17864-70.
47. Nomura M, Yamagishi S, Harada S, Yamashima T, Yamashita J, Yamamoto H. Placenta growth factor (PIGF) mRNA expression in brain tumors. J Neuro-Oncology 1998; 40:123-30.
48. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: A cytoplasmic anchor for p53. Cell 2003; 112:29-40.
49. Lee EJ, Mircean C, Shmulvich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Molecular Cancer 2005; 4:7-15.